YCMGA
UTHR icon

York Capital Management Global Advisors’s United Therapeutics UTHR Stock Holding History

York Capital Management Global Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-372,240
Closed -$64.2M – 130
2015
Q1 		$64.2M Buy
+372,240
New +$56.7M 0.44% 58

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

York Capital Management Global Advisors's UTHR Position: Q2 2015 in Review

York Capital Management Global Advisors sold out of United Therapeutics (UTHR) in Q2 2015, closing a stake of 372,240 shares — an estimated $64.2M sold.

York Capital Management Global Advisors first reported a position in UTHR in Q1 2015 and held it in 1 quarter. The position peaked at $64.2M in Q1 2015. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2015.

  • York Capital Management Global Advisors reported no remaining United Therapeutics position as of Q2 2015 after selling out during the quarter.
  • York Capital Management Global Advisors sold 372,240 United Therapeutics shares in Q2 2015, an estimated $64.2M.
  • York Capital Management Global Advisors first reported a position in United Therapeutics in Q1 2015 and held it in 1 quarter.
  • York Capital Management Global Advisors's United Therapeutics position peaked at $64.2M in Q1 2015.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2015.

Based on York Capital Management Global Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.